61.8 F
New York
Wednesday, May 18, 2022

AstraZeneca [NYSE: AZN] Concludes COVID-19 Vaccine Supply Deal In Europe

Must read

AstraZeneca PLC [NYSE: AZN] disclosed Friday it has closed the supply deal of 400 million doses of the AZD1222 COVID-19 vaccine with European Commission.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


This new deal will allow European member states to access the vaccine in an equitable manner at no profit amid pandemic.

This new supply deal between AZN & European Commission also gives rights to European member states to redirect doses to other European countries.

[candlestick-chart id=”2″]

Shares of AstraZeneca exhibited a change of 1.66% at a closing price of $55.80 during the trading session of Thursday. It has day low range $55.69 and a day high range of $56.43.

In the past 52-weeks of trading, AstraZeneca shares fluctuated between the low of $36.15 and a high of $64.94. It has moved up 54.36% from its 52-weeks low and moved down -14.07% from its 52-weeks high.

If we turn our focus on its profitability, its return on assets (ROA) is 3.60%, return on investment (ROI) is 8.30%, and ROE is 17.80%.

Furthermore, it has a Gross Margin of 80.30%, a Profit Margin of 8.40%, and an Operating Margin of 14.90%.

Continuing to look at its liquidity, its current ratio is 0.80. Likewise, its quick ratio is 0.60. AstraZeneca has a total debt to equity ratio of 1.61 and a long term debt to equity ratio of 1.28.

AZD1222 has shown a positive result in July 2020. AZD1222 has generated robust immune responses against SARS-CoV-19. The clinical trial of AZD-1222 is ongoing around the globe.

Furthermore, its trial entered into phase I/II in South Africa and has started phase II/III in Brazil and the UK.

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. AZD1222 uses a replication-deficient chimpanzee viral vector.

It based on a weakened version of a common cold virus that causes infections in chimpanzees. Additionally, it also contains the genetic material of the SARS-CoV-2 virus spike protein.

More articles

Latest article